Source: International Congress 2015 – Emerging strategies for airway disease treatments
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Srinivasa Honnegowda (Navi Mumbai, India), Srinivasa Honnegowda, Abraham Thomas, Sachin Chaudhari, Sanjib Das, Daisy Shah, Malini Bajpai, Indrani Sarkar, Abhay Kulkarni, Girish Gudi, Satyawan Jadhav, Neelima Khairatkar-Joshi. LATE-BREAKING ABSTRACT: Novel inhaled ROR/c inhibitor for potential treatment of COPD. Eur Respir J 2015; 46: Suppl. 59, 4367

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: Anti-inflammatory effect of a novel inhaled dual PDE3/4 inhibitor RPL554 in man, a unique “first-in-class” drug for the treatment of COPD & asthma Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013 LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results) Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice Year: 2015 The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015 MUC1-CT mediates corticosteroid responses in COPD Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 LATE-BREAKING ABSTRACT: A Phase 1b study of PUR0200, a novel tiotropium formulation, in COPD patients Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 The mechanisms of antiinflammatory effect of mucolytic therapy Source: International Congress 2014 – Predictors Year: 2014 LATE-BREAKING ABSTRACT: Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: Results of the FULFIL trial Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities Year: 2016 Comparison of protective effect of bronchodilators in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Additive effect of targeted lung denervation plus drug in patients with COPD Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 LATE-BREAKING ABSTRACT: Effects of a fixed dose once-daily triple drug combination in smokers and non-smokers with COPD Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 Do inhaled corticosteroids reduce the frequent exacerbator phenotype in COPD - A little help by a multicenter survey Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 LATE-BREAKING ABSTRACT: An algorithm for the identification of clinical COPD phenotypes in daily practice Source: International Congress 2016 – COPD diagnosis and management Year: 2016 Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 The adherence to inhaled drugs in COPD patients: Effect on survival Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Lung function, symptoms and prescription of inhaled steroids and long acting β2 agonists in patients managed by an integrated COPD team Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 LATE-BREAKING ABSTRACT: PT003, a novel co-suspension MDI glycopyrronium/formoterol fixed-dose combination is superior to monocomponents in patients with COPD Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015